INNOVENT BIO (01801) has a current Price-to-Book (P/B) ratio of 8.60. Compared to its 3-year average P/B ratio of 5.80, the current P/B ratio is approximately 48.27% higher. Relative to its 5-year average P/B ratio of 5.81, the current P/B ratio is about 48.19% higher. INNOVENT BIO (01801) has a Forward Free Cash Flow (FCF) yield of approximately 1.19%. Compared to its 3-year average FCF yield of -1.62%, the current FCF yield is approximately -173.28% lower. Relative to its 5-year average FCF yield of -3.07%, the current FCF yield is about -138.70% lower.

Performance Decomposition

AI Analysis

Market capitalization of 01801 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 01801 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 01801 currently overvalued or undervalued?

What is INNOVENT BIO (01801) fair value?

01801's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of INNOVENT BIO (01801) is between 39.69 to 114.17 according to relative valuation method.

How does 01801's valuation metrics compare to the industry average?

The average P/S ratio for 01801's competitors is 0.00, providing a benchmark for relative valuation. INNOVENT BIO Corp (01801) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for INNOVENT BIO (01801) as of Mar 03 2026?

As of Mar 03 2026, INNOVENT BIO (01801) has a P/B ratio of 8.60. This indicates that the market values 01801 at 8.60 times its book value.

What is the current FCF Yield for INNOVENT BIO (01801) as of Mar 03 2026?

As of Mar 03 2026, INNOVENT BIO (01801) has a FCF Yield of 1.19%. This means that for every dollar of INNOVENT BIO's market capitalization, the company generates 1.19 cents in free cash flow.

What is the current Forward P/E ratio for INNOVENT BIO (01801) as of Mar 03 2026?

As of Mar 03 2026, INNOVENT BIO (01801) has a Forward P/E ratio of 50.91. This means the market is willing to pay $50.91 for every dollar of INNOVENT BIO's expected earnings over the next 12 months.

What is the current Forward P/S ratio for INNOVENT BIO (01801) as of Mar 03 2026?

As of Mar 03 2026, INNOVENT BIO (01801) has a Forward P/S ratio of 8.00. This means the market is valuing 01801 at $8.00 for every dollar of expected revenue over the next 12 months.

01801 Valuation